APO Research
Talk to an analyst

APO RESEARCH · REPORT

Women's Health Care Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Women's Health Care Drugs Market Outlook and Growth Opportunities 2026

31 December 2025196 pages

Choose your research edition.

Industry ResearchWomen's Health Care Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Women's Health Care Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Women's Health Care Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Women's Health Care Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Women's Health Care Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Women's Health Care Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Women's Health Care Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Women's Health Care Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Women's Health Care Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Women's Health Care Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Women's Health Care Drugs market include Merck & Co, Mylan N.V., Lupin, Pfizer Inc., Ferring Pharmaceuticals, Bayer AG, Amgen, Allergan and Blairex Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Women's Health Care Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Women's Health Care Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Women's Health Care Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Women's Health Care Drugs market.

Women's Health Care Drugs Segment by Company

Merck & Co

Mylan N.V.

Lupin

Pfizer Inc.

Ferring Pharmaceuticals

Bayer AG

Amgen

Allergan

Blairex Laboratories

Apothecus Pharmaceutical

Agile Therapeutics

Women's Health Care Drugs Segment by Type

Endometriosis

Postmenopausal Osteoporosis

Menopause

Hormonal Infertility

Polycystic Ovary Syndrome

Contraceptives

Others

Women's Health Care Drugs Segment by Application

Prescription Drugs

Non-prescription Drugs

Women's Health Care Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Women's Health Care Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Women's Health Care Drugs key companies, revenue, market share, and recent developments.

3. To split the Women's Health Care Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Women's Health Care Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Women's Health Care Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Women's Health Care Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women's Health Care Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Women's Health Care Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women's Health Care Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Women's Health Care Drugs industry.

Chapter 3: Detailed analysis of Women's Health Care Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Women's Health Care Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Women's Health Care Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Women's Health Care Drugs Industry Trends Table 2. Women's Health Care Drugs Industry Drivers Table 3. Women's Health Care Drugs Industry Opportunities and Challenges Table 4. Women's Health Care Drugs Industry Restraints Table 5. Global Women's Health Care Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Women's Health Care Drugs Revenue Share by Company (2021-2026) Table 7. Global Women's Health Care Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Women's Health Care Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Women's Health Care Drugs Company, Product Type & Application Table 10. Global Women's Health Care Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Women's Health Care Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Endometriosis Table 15. Significant Companies of Postmenopausal Osteoporosis Table 16. Significant Companies of Menopause Table 17. Significant Companies of Hormonal Infertility Table 18. Significant Companies of Polycystic Ovary Syndrome Table 19. Significant Companies of Contraceptives Table 20. Significant Companies of Others Table 21. Global Women's Health Care Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Women's Health Care Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Women's Health Care Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Women's Health Care Drugs Sales Value Share by Type (2021-2026) Table 25. Global Women's Health Care Drugs Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Prescription Drugs Table 27. Significant Companies of Non-prescription Drugs Table 28. Global Women's Health Care Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Women's Health Care Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Women's Health Care Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Women's Health Care Drugs Sales Value Share by Application (2021-2026) Table 32. Global Women's Health Care Drugs Sales Value Share by Application (2027-2032) Table 33. Global Women's Health Care Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Women's Health Care Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Women's Health Care Drugs Sales Value Share by Region (2021-2026) Table 36. Global Women's Health Care Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Women's Health Care Drugs Sales Value Share by Region (2027-2032) Table 38. Global Women's Health Care Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Women's Health Care Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Women's Health Care Drugs Sales Value Market Share by Country (2021-2026) Table 41. Global Women's Health Care Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Women's Health Care Drugs Sales Value Market Share by Country (2027-2032) Table 43. Merck & Co Company Information Table 44. Merck & Co Business Overview Table 45. Merck & Co Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Merck & Co Women's Health Care Drugs Product Portfolio Table 47. Merck & Co Recent Development Table 48. Mylan N.V. Company Information Table 49. Mylan N.V. Business Overview Table 50. Mylan N.V. Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Mylan N.V. Women's Health Care Drugs Product Portfolio Table 52. Mylan N.V. Recent Development Table 53. Lupin Company Information Table 54. Lupin Business Overview Table 55. Lupin Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Lupin Women's Health Care Drugs Product Portfolio Table 57. Lupin Recent Development Table 58. Pfizer Inc. Company Information Table 59. Pfizer Inc. Business Overview Table 60. Pfizer Inc. Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Pfizer Inc. Women's Health Care Drugs Product Portfolio Table 62. Pfizer Inc. Recent Development Table 63. Ferring Pharmaceuticals Company Information Table 64. Ferring Pharmaceuticals Business Overview Table 65. Ferring Pharmaceuticals Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Ferring Pharmaceuticals Women's Health Care Drugs Product Portfolio Table 67. Ferring Pharmaceuticals Recent Development Table 68. Bayer AG Company Information Table 69. Bayer AG Business Overview Table 70. Bayer AG Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bayer AG Women's Health Care Drugs Product Portfolio Table 72. Bayer AG Recent Development Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Amgen Women's Health Care Drugs Product Portfolio Table 77. Amgen Recent Development Table 78. Allergan Company Information Table 79. Allergan Business Overview Table 80. Allergan Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Allergan Women's Health Care Drugs Product Portfolio Table 82. Allergan Recent Development Table 83. Blairex Laboratories Company Information Table 84. Blairex Laboratories Business Overview Table 85. Blairex Laboratories Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Blairex Laboratories Women's Health Care Drugs Product Portfolio Table 87. Blairex Laboratories Recent Development Table 88. Apothecus Pharmaceutical Company Information Table 89. Apothecus Pharmaceutical Business Overview Table 90. Apothecus Pharmaceutical Women's Health Care Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Apothecus Pharmaceutical Women's Health Care Drugs Product Portfolio Table 92. Apothecus Pharmaceutical Recent Development Table 93. Agile Therapeutics Company Information Table 94. Agile Therapeutics Business Overview Table 95. Agile Therapeutics Women's Health Care Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Agile Therapeutics Women's Health Care Drugs Product Portfolio Table 97. Agile Therapeutics Recent Development Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Women's Health Care Drugs Product Image Figure 2. Global Women's Health Care Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Women's Health Care Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Women's Health Care Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Endometriosis Image Figure 8. Postmenopausal Osteoporosis Image Figure 9. Menopause Image Figure 10. Hormonal Infertility Image Figure 11. Polycystic Ovary Syndrome Image Figure 12. Contraceptives Image Figure 13. Others Image Figure 14. Global Women's Health Care Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Women's Health Care Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Women's Health Care Drugs Sales Value Share by Type (2021-2032) Figure 17. Prescription Drugs Image Figure 18. Non-prescription Drugs Image Figure 19. Global Women's Health Care Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Women's Health Care Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Women's Health Care Drugs Sales Value Share by Application (2021-2032) Figure 22. Global Women's Health Care Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Women's Health Care Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Women's Health Care Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. North America Women's Health Care Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Women's Health Care Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Women's Health Care Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Women's Health Care Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Women's Health Care Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Women's Health Care Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. South America Women's Health Care Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Women's Health Care Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Women's Health Care Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Women's Health Care Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Endometriosis
  • Postmenopausal Osteoporosis
  • Menopause
  • Hormonal Infertility
  • Polycystic Ovary Syndrome
  • Contraceptives
  • Others
Applications
  • Prescription Drugs
  • Non-prescription Drugs
Companies covered
  • Merck & Co
  • Mylan N.V.
  • Lupin
  • Pfizer Inc.
  • Ferring Pharmaceuticals
  • Bayer AG
  • Amgen
  • Allergan
  • Blairex Laboratories
  • Apothecus Pharmaceutical
  • Agile Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Women's Health Care Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Women's Health Care Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Women's Health Care Drugs Market Dynamics
  1. 2.1 Women's Health Care Drugs Industry Trends
  2. 2.2 Women's Health Care Drugs Industry Drivers
  3. 2.3 Women's Health Care Drugs Industry Opportunities and Challenges
  4. 2.4 Women's Health Care Drugs Industry Restraints
3 Women's Health Care Drugs Market by Company
  1. 3.1 Global Women's Health Care Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Women's Health Care Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Women's Health Care Drugs Company Ranking (2024-2026)
  4. 3.4 Global Women's Health Care Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Women's Health Care Drugs Company Product Type and Application
  6. 3.6 Global Women's Health Care Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Women's Health Care Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Women's Health Care Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Women's Health Care Drugs Market by Type
  1. 4.1 Women's Health Care Drugs Type Introduction
  2. 4.1.1 Endometriosis
  3. 4.1.2 Postmenopausal Osteoporosis
  4. 4.1.3 Menopause
  5. 4.1.4 Hormonal Infertility
  6. 4.1.5 Polycystic Ovary Syndrome
  7. 4.1.6 Contraceptives
  8. 4.1.7 Others
  9. 4.2 Global Women's Health Care Drugs Sales Value by Type
  10. 4.2.1 Global Women's Health Care Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Women's Health Care Drugs Sales Value by Type (2021-2032)
  12. 4.2.3 Global Women's Health Care Drugs Sales Value Share by Type (2021-2032)
5 Women's Health Care Drugs Market by Application
  1. 5.1 Women's Health Care Drugs Application Introduction
  2. 5.1.1 Prescription Drugs
  3. 5.1.2 Non-prescription Drugs
  4. 5.2 Global Women's Health Care Drugs Sales Value by Application
  5. 5.2.1 Global Women's Health Care Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Women's Health Care Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Women's Health Care Drugs Sales Value Share by Application (2021-2032)
6 Women's Health Care Drugs Regional Value Analysis
  1. 6.1 Global Women's Health Care Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Women's Health Care Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Women's Health Care Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Women's Health Care Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Women's Health Care Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Women's Health Care Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Women's Health Care Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Women's Health Care Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Women's Health Care Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Women's Health Care Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Women's Health Care Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Women's Health Care Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Women's Health Care Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Women's Health Care Drugs Sales Value Share by Country, 2025 VS 2032
7 Women's Health Care Drugs Country-level Value Analysis
  1. 7.1 Global Women's Health Care Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Women's Health Care Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Women's Health Care Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Women's Health Care Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Women's Health Care Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Women's Health Care Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Women's Health Care Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co
  2. 8.1.1 Merck & Co Company Information
  3. 8.1.2 Merck & Co Business Overview
  4. 8.1.3 Merck & Co Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co Women's Health Care Drugs Product Portfolio
  6. 8.1.5 Merck & Co Recent Developments
  7. 8.2 Mylan N.V.
  8. 8.2.1 Mylan N.V. Company Information
  9. 8.2.2 Mylan N.V. Business Overview
  10. 8.2.3 Mylan N.V. Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mylan N.V. Women's Health Care Drugs Product Portfolio
  12. 8.2.5 Mylan N.V. Recent Developments
  13. 8.3 Lupin
  14. 8.3.1 Lupin Company Information
  15. 8.3.2 Lupin Business Overview
  16. 8.3.3 Lupin Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lupin Women's Health Care Drugs Product Portfolio
  18. 8.3.5 Lupin Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Women's Health Care Drugs Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 Ferring Pharmaceuticals
  26. 8.5.1 Ferring Pharmaceuticals Company Information
  27. 8.5.2 Ferring Pharmaceuticals Business Overview
  28. 8.5.3 Ferring Pharmaceuticals Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ferring Pharmaceuticals Women's Health Care Drugs Product Portfolio
  30. 8.5.5 Ferring Pharmaceuticals Recent Developments
  31. 8.6 Bayer AG
  32. 8.6.1 Bayer AG Company Information
  33. 8.6.2 Bayer AG Business Overview
  34. 8.6.3 Bayer AG Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer AG Women's Health Care Drugs Product Portfolio
  36. 8.6.5 Bayer AG Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Women's Health Care Drugs Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Allergan
  44. 8.8.1 Allergan Company Information
  45. 8.8.2 Allergan Business Overview
  46. 8.8.3 Allergan Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Allergan Women's Health Care Drugs Product Portfolio
  48. 8.8.5 Allergan Recent Developments
  49. 8.9 Blairex Laboratories
  50. 8.9.1 Blairex Laboratories Company Information
  51. 8.9.2 Blairex Laboratories Business Overview
  52. 8.9.3 Blairex Laboratories Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Blairex Laboratories Women's Health Care Drugs Product Portfolio
  54. 8.9.5 Blairex Laboratories Recent Developments
  55. 8.10 Apothecus Pharmaceutical
  56. 8.10.1 Apothecus Pharmaceutical Company Information
  57. 8.10.2 Apothecus Pharmaceutical Business Overview
  58. 8.10.3 Apothecus Pharmaceutical Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Apothecus Pharmaceutical Women's Health Care Drugs Product Portfolio
  60. 8.10.5 Apothecus Pharmaceutical Recent Developments
  61. 8.11 Agile Therapeutics
  62. 8.11.1 Agile Therapeutics Company Information
  63. 8.11.2 Agile Therapeutics Business Overview
  64. 8.11.3 Agile Therapeutics Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Agile Therapeutics Women's Health Care Drugs Product Portfolio
  66. 8.11.5 Agile Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst